<DOC>
	<DOCNO>NCT00336518</DOCNO>
	<brief_summary>Primary objective measure sustain viral response give continuation prolongation combine Pegasys &amp; Copegus treatment Secondary objective measure histological response give continuation prolongation combine Pegasys &amp; Copegus treatment measure non-invasive method</brief_summary>
	<brief_title>Continuing Treatment With Pegasys Copegus</brief_title>
	<detailed_description>Prospective , multicentre , randomize , open-label comparative study According national guideline management patient chronic viral hepatitis , patient need stop therapy achieve response . These patient enter study two time point : - week 16 , HCV RNS PCR measure week 12 positive serum ALT &gt; 1ULN , decrease - week 28 , HCV RNS PCR measure week 24 still positive , serum ALT &lt; 2ULN . Patients randomize one follow arm : - S ( standard ) group : Pegasys &amp; Copegus combine therapy 180 mcg/week &amp; weight/based 1000-1200 mg/day total 48 week treatment - P ( prolong ) group : Pegasys &amp; Copegus combine therapy 180 mcg/week &amp; -weight/based 1000-1200 mg/day total 72 week treatment . After complete treatment period patient enter 24-week follow .</detailed_description>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<criteria>Male female patient 18 65 year age chronically infect genotype 1 HCV receiving combine Pegasys &amp; Copegus treatment first time inline valid treatment guideline approve National Interferon Committee ( see attach guideline ) Subgroup 1 : Positive HCV PCR result week 12 ongoing treatment ALT &gt; 1ULN , value decrease week 12 Subgroup 2 : ALT normal PCR positive week 12 , therefore combined treatment could continue week 12 24 base approve guideline Positive HCV RNA PCR week 24 ongoing treatment GPT &lt; 2 ULN week 24 ongoing treatment . Women ongoing pregnancy breast feed Therapy systemic antineoplastic immunomodulatory treatment inclusion within 6 month prior Any investigational drug usage inclusion within 6 week prior Co/infection hepatitis A , B HIV Any chronic liver disease HCV infection Sign symptom hepatocellular carcinoma Decompensated liver disease History depression relevant psychiatric disease , opinion psychiatrist neurologist , contraindicate study therapy Uncontrolled thyroid dysfunction Severe retinopathy Evidence regular alcohol consumption inclusion within 1 year prior Any side effect probably cause ongoing combined treatment , opinion investigator , contraindicate continuation therapy necessitates dose reduction drug combination therapy Unwillingness provide inform consent Subgroup 1 : Laboratory finding week 16 ongoing combine Pegasys &amp; Copegus treatment : ANC &lt; 1000/mm3 PLT &lt; 75.000/mm3 hemoglobin &lt; 10g/dl creatinine &gt; 1,5 ULN Subgroup 2 : Laboratory finding week 28 ongoing combine Pegasys &amp; Copegus treatment : ANC &lt; 1000/mm3 PLT &lt; 75.000/mm3 hemoglobin &lt; 10g/dl creatinine &gt; 1,5 ULN</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2005</verification_date>
</DOC>